Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 11-Jul-22 4:11 PM View:  | Wagner Kristie Ann VP, Principal Fin & Acct Off | Entasis Therapeutics Holdin... (ETTX) | 11-Jul-22 | Disposition | 80,500 | -- | -- | (100%) 80.5K to 0 | |
| 11-Jul-22 4:09 PM View: | Ronsheim Matthew Chief of Pharma Sciences & MFG | Entasis Therapeutics Holdin... (ETTX) | 11-Jul-22 | Disposition | 150,000 | -- | -- | (100%) 150.0K to 0 | |
| 11-Jul-22 4:07 PM View: | Mueller John Patrick Chief Development Officer | Entasis Therapeutics Holdin... (ETTX) | 11-Jul-22 | Disposition | 150,000 | -- | -- | (100%) 150.0K to 0 | |
| 11-Jul-22 4:06 PM View: | Keiley Elizabeth M General Counsel | Entasis Therapeutics Holdin... (ETTX) | 11-Jul-22 | Disposition | 150,000 | -- | -- | (100%) 150.0K to 0 | |
| 11-Jul-22 4:07 PM View: | Meek David D. Director | Entasis Therapeutics Holdin... (ETTX) | 11-Jul-22 | Disposition | 27,500 | $2.20 | $60,500.00 | (100%) 27.5K to 0 | |
| 11-Jul-22 4:08 PM View: | Perros Manoussos President and CEO Director | Entasis Therapeutics Holdin... (ETTX) | 11-Jul-22 | Disposition | 478,500 | -- | -- | (100%) 478.5K to 0 | |
| 11-Jul-22 4:03 PM View: | Altarac David Chief Medical Officer | Entasis Therapeutics Holdin... (ETTX) | 11-Jul-22 | Disposition | 150,000 | -- | -- | (100%) 150.0K to 0 | |
| 13-Jul-22 9:27 PM View: | Theravance Inc 10% Owner | Entasis Therapeutics Holdin... (ETTX) | 11-Jul-22 | Purchase | 7,598,810 | $2.20 | $16,717,400.00 | 12% 62.02M to 69.61M | |
| 11-Jul-22 4:06 PM View: | Mayer Howard Director | Entasis Therapeutics Holdin... (ETTX) | 11-Jul-22 | Disposition | 27,500 | $2.20 | $60,500.00 | (100%) 27.5K to 0 | |
| 11-Jul-22 4:09 PM View: | Tommasi Rubin Chief Scientific Officer | Entasis Therapeutics Holdin... (ETTX) | 11-Jul-22 | Disposition | 150,000 | -- | -- | (100%) 150.0K to 0 | |
| 11-Jul-22 4:04 PM View: | Behanna Heather Director | Entasis Therapeutics Holdin... (ETTX) | 11-Jul-22 | Disposition | 27,500 | $2.20 | $60,500.00 | (100%) 27.5K to 0 | |
| 11-Jul-22 4:05 PM View: | Hastings David C Director | Entasis Therapeutics Holdin... (ETTX) | 11-Jul-22 | Disposition | 27,500 | $2.20 | $60,500.00 | (100%) 27.5K to 0 | |
| 11-Jul-22 4:10 PM View: | Triola Anna Diaz Chief Commercial Officer | Entasis Therapeutics Holdin... (ETTX) | 11-Jul-22 | Disposition | 125,000 | -- | -- | (100%) 125.0K to 0 | |
| 13-Jul-22 9:27 PM View: | Theravance Inc 10% Owner | Entasis Therapeutics Holdin... (ETTX) | 08-Jul-22 | Private Purchase | 11,671,700 | $2.20 | $25,677,700.00 | 23% 50.34M to 62.02M | |
| 11-Jul-22 4:06 PM View: | Mayer Howard Director | Entasis Therapeutics Holdin... (ETTX) | 07-Jul-22 | Disposition (change in control) | 22,000 | $2.20 | $48,400.00 | (100%) 22.0K to 0 | |
| 11-Jul-22 4:09 PM View: | Tommasi Rubin Chief Scientific Officer | Entasis Therapeutics Holdin... (ETTX) | 07-Jul-22 | Disposition (change in control) | 39,596 | $2.20 | $87,111.20 | (100%) 39.6K to 0 | |
| 11-Jul-22 4:04 PM View: | Behanna Heather Director | Entasis Therapeutics Holdin... (ETTX) | 07-Jul-22 | Disposition (change in control) | 22,000 | $2.20 | $48,400.00 | (100%) 22.0K to 0 | |
| 11-Jul-22 4:05 PM View: | Hastings David C Director | Entasis Therapeutics Holdin... (ETTX) | 07-Jul-22 | Disposition (change in control) | 22,000 | $2.20 | $48,400.00 | (100%) 22.0K to 0 | |
| 11-Jul-22 4:07 PM View: | Mueller John Patrick Chief Development Officer | Entasis Therapeutics Holdin... (ETTX) | 07-Jul-22 | Disposition (change in control) | 17,092 | $2.20 | $37,602.40 | (100%) 17.09K to 0 | |
| 11-Jul-22 4:06 PM View: | Keiley Elizabeth M General Counsel | Entasis Therapeutics Holdin... (ETTX) | 07-Jul-22 | Disposition (change in control) | 17,572 | $2.20 | $38,658.40 | (100%) 17.57K to 0 | |
| 11-Jul-22 4:09 PM View: | Ronsheim Matthew Chief of Pharma Sciences & MFG | Entasis Therapeutics Holdin... (ETTX) | 07-Jul-22 | Disposition (change in control) | 17,572 | $2.20 | $38,658.40 | (100%) 17.57K to 0 | |
| 11-Jul-22 4:03 PM View: | Altarac David Chief Medical Officer | Entasis Therapeutics Holdin... (ETTX) | 07-Jul-22 | Disposition (change in control) | 17,572 | $2.20 | $38,658.40 | (100%) 17.57K to 0 | |
| 11-Jul-22 4:07 PM View: | Meek David D. Director | Entasis Therapeutics Holdin... (ETTX) | 07-Jul-22 | Disposition (change in control) | 22,000 | $2.20 | $48,400.00 | (100%) 22.0K to 0 | |
| 11-Jul-22 4:08 PM View: | Perros Manoussos President and CEO Director | Entasis Therapeutics Holdin... (ETTX) | 07-Jul-22 | Disposition (change in control) | 56,072 | $2.20 | $123,358.00 | (100%) 56.07K to 0 | |
| 25-Feb-22 4:30 PM View: | Wagner Kristie Ann VP, Principal Fin & Acct Off | Entasis Therapeutics Holdin... (ETTX) | 24-Feb-22 | Grant | 10,000 | -- | -- | 14% 70.5K to 80.5K | |
| 19-Jan-22 4:04 PM View: | Ronsheim Matthew See Remarks | Entasis Therapeutics Holdin... (ETTX) | 18-Jan-22 | Grant | 125,000 | -- | -- | 294% 42.57K to 167.57K | |
| 19-Jan-22 4:00 PM View: | Altarac David Chief Medical Officer | Entasis Therapeutics Holdin... (ETTX) | 18-Jan-22 | Grant | 125,000 | -- | -- | 294% 42.57K to 167.57K | |
| 19-Jan-22 4:03 PM View: | Mayer Howard Director | Entasis Therapeutics Holdin... (ETTX) | 18-Jan-22 | Grant | 27,500 | -- | -- | 125% 22.0K to 49.5K | |
| 19-Jan-22 4:05 PM View: | Gutch Michael See Remarks | Entasis Therapeutics Holdin... (ETTX) | 18-Jan-22 | Grant | 125,000 | -- | -- | 294% 42.57K to 167.57K | |
| 19-Jan-22 4:05 PM View: | Tommasi Rubin Chief Scientific Officer | Entasis Therapeutics Holdin... (ETTX) | 18-Jan-22 | Grant | 125,000 | -- | -- | 194% 64.6K to 189.6K | |
| 19-Jan-22 4:02 PM View: | Behanna Heather Director | Entasis Therapeutics Holdin... (ETTX) | 18-Jan-22 | Grant | 27,500 | -- | -- | 125% 22.0K to 49.5K | |
| 19-Jan-22 4:01 PM View: | Hastings David C Director | Entasis Therapeutics Holdin... (ETTX) | 18-Jan-22 | Grant | 27,500 | -- | -- | 125% 22.0K to 49.5K | |
| 19-Jan-22 4:00 PM View: | Triola Anna Diaz Chief Commercial Officer | Entasis Therapeutics Holdin... (ETTX) | 18-Jan-22 | Grant | 125,000 | -- | -- | 100% 0 to 125.0K | |
| 19-Jan-22 4:04 PM View: | Perros Manoussos See Remarks | Entasis Therapeutics Holdin... (ETTX) | 18-Jan-22 | Grant | 125,000 | -- | -- | 31% 409.57K to 534.57K | |
| 19-Jan-22 4:03 PM View: | Mueller John Patrick Chief Development Officer | Entasis Therapeutics Holdin... (ETTX) | 18-Jan-22 | Grant | 125,000 | -- | -- | 297% 42.09K to 167.09K | |
| 19-Jan-22 4:02 PM View: | Keiley Elizabeth M General Counsel | Entasis Therapeutics Holdin... (ETTX) | 18-Jan-22 | Grant | 125,000 | -- | -- | 294% 42.57K to 167.57K | |
| 19-Jan-22 4:01 PM View: | Meek David D. Director | Entasis Therapeutics Holdin... (ETTX) | 18-Jan-22 | Grant | 27,500 | -- | -- | 125% 22.0K to 49.5K | |
| 03-Nov-21 4:02 PM View: | Tommasi Rubin Chief Scientific Officer | Entasis Therapeutics Holdin... (ETTX) | 02-Nov-21 | Payment of Exercise | 3,669 | $2.94 | $10,786.90 | (5%) 68.27K to 64.6K | |
| 03-Nov-21 4:05 PM View: | Ronsheim Matthew Chief, Pharma Sciences & MFG. | Entasis Therapeutics Holdin... (ETTX) | 02-Nov-21 | Payment of Exercise | 3,669 | $2.94 | $10,786.90 | (8%) 46.24K to 42.57K | |
| 03-Nov-21 4:03 PM View: | Mueller John Patrick Chief Development Officer | Entasis Therapeutics Holdin... (ETTX) | 02-Nov-21 | Payment of Exercise | 3,907 | $2.94 | $11,486.60 | (8%) 46.0K to 42.09K | |
| 03-Nov-21 4:04 PM View: | Keiley Elizabeth M General Counsel | Entasis Therapeutics Holdin... (ETTX) | 02-Nov-21 | Payment of Exercise | 3,669 | $2.94 | $10,786.90 | (8%) 46.24K to 42.57K | |
| 03-Nov-21 4:02 PM View: | Gutch Michael CFO and Chief Business Officer | Entasis Therapeutics Holdin... (ETTX) | 02-Nov-21 | Payment of Exercise | 3,669 | $2.94 | $10,786.90 | (8%) 46.24K to 42.57K | |
| 03-Nov-21 4:04 PM View: | Altarac David Chief Medical Officer | Entasis Therapeutics Holdin... (ETTX) | 02-Nov-21 | Payment of Exercise | 3,669 | $2.94 | $10,786.90 | (8%) 46.24K to 42.57K | |
| 03-Nov-21 4:03 PM View: | Perros Manoussos President and CEO Director | Entasis Therapeutics Holdin... (ETTX) | 02-Nov-21 | Payment of Exercise | 11,704 | $2.94 | $34,409.80 | (8%) 147.53K to 135.82K | |
| 20-Oct-21 4:08 PM View: | Tommasi Rubin Chief Scientific Officer | Entasis Therapeutics Holdin... (ETTX) | 19-Oct-21 | Grant | 25,000 | -- | -- | 53% 47.02K to 72.02K | |
| 20-Oct-21 4:06 PM View: | Altarac David Chief Medical Officer | Entasis Therapeutics Holdin... (ETTX) | 19-Oct-21 | Sale | 3,759 | $3.19 | $11,991.20 | (8%) 50.0K to 46.24K | |
| 20-Oct-21 4:05 PM View: | Ronsheim Matthew See Remarks | Entasis Therapeutics Holdin... (ETTX) | 19-Oct-21 | Grant | 25,000 | -- | -- | 100% 25.0K to 50.0K | |
| 20-Oct-21 4:09 PM View: | Gutch Michael See Remarks | Entasis Therapeutics Holdin... (ETTX) | 19-Oct-21 | Grant | 25,000 | -- | -- | 100% 25.0K to 50.0K | |
| 20-Oct-21 4:14 PM View: | Perros Manoussos See Remarks Director | Entasis Therapeutics Holdin... (ETTX) | 19-Oct-21 | Sale | 11,974 | $3.19 | $38,197.10 | (8%) 159.5K to 147.53K | |
| 20-Oct-21 4:05 PM View: | Ronsheim Matthew See Remarks | Entasis Therapeutics Holdin... (ETTX) | 19-Oct-21 | Sale | 3,759 | $3.19 | $11,991.20 | (8%) 50.0K to 46.24K |
